Sibylla’s PPI-FIT technology explores protein folding intermediates as unique pharmacological targets, enabling the discovery of Folding Interfering Degraders.
Sibylla’s key differentiator is its protein folding computational platform, which enables the reconstruction of the complex series of conformational rearrangements underlying the process of protein folding at an all-atom level of detail.
A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.
V-Bio Ventures is an independent venture capital firm that builds and finances early-stage life sciences companies across Europe, partnering with VIB in Belgium.
Recent computational advancements in the simulation of biochemical processes allow investigating the mechanisms involved in protein regulation with realistic physics-based models, at an atomistic level of resolution.
